Genocea Biosciences, Inc. Announces Resignation of Jonathan Poole as Chief Financial Officer, Effective March 23, 2018
March 10, 2018 at 02:49 am IST
Share
On March 6, 2018, Jonathan Poole delivered his resignation as Chief Financial Officer of Genocea Biosciences, Inc., effective March 23, 2018, to pursue another professional opportunity. Mr. Poole will assist in the transition of the Chief Financial Officer role until his departure from the Company. The Company is currently conducting a search process for Mr. Poole's replacement and, pending the conclusion of that search, William Clark, President and Chief Executive Officer of the Company, will assume the duties of the Company's principal financial officer and principal accounting officer.
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The Company has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.